Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Amicus Therapeutics

Amicus Therapeutics
2002 FOUNDED
PUBLIC STATUS
501-600 EMPLOYEES
FOLD STOCK SYMBOL
4 INVESTMENTS
$9.79 SHARE PRICE (As of Tuesday Closing)
Description

Amicus Therapeutics Inc is a global biotechnology company that aims to treat rare and orphan diseases. The company's strategy focuses on global capacity with an international infrastructure, late-stage product acquisition, and biologics manufacturing. Amicus leverages its pharmacological technology to develop treatments for human genetic diseases by targeting mutated proteins. The company utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products.

Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • 1 Cedar Brook Drive
  • Cranbury, NJ 08512
  • United States

+1 (609) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Amicus Therapeutics’s full profile, request a free trial.

Amicus Therapeutics Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$7.11 - $14.62 $2.49B $9.76 -$1.54 3.5M 255M

Amicus Therapeutics Financials Summary

In Thousands,
USD
TTM
30-Sep-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 1,654,446 1,567,822 2,142,729 560,986
Revenue 159,588 91,245 36,930 4,958
EBITDA (325,970) (332,932) (432,384) (196,743)
Net Income (344,740) (348,995) (284,002) (200,042)
Total Assets 882,292 789,951 627,024 1,036,845
Total Debt 205,302 321,740 164,167 154,747
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Amicus Therapeutics Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Amicus Therapeutics‘s full profile, request access.

Request full access to PitchBook

Amicus Therapeutics Competitors (19)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ibio Corporation Newark, DE 00
00000000 000000000 Formerly VC-backed Carmiel, Israel 000 000.00 00000000000 000.00
000000 00000000000 Formerly VC-backed San Diego, CA 00 00000 00000000000 00000
00000000 Formerly VC-backed Rockville, MD 0 000.00 00000000 000.00
000000000 00000000 Corporation Basking Ridge, NJ 00 00000 000000000 00000
To view this company’s complete list of competitors, request access »

Amicus Therapeutics Acquisitions (4)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 20-Sep-2018 000000000000000000 00000 Biotechnology 0000 0000000 00
000000 05-Jul-2016 000000000000000000 000.00 Biotechnology 0000 0000000 00
00000000 30-Sep-2015 000000000000000000 00000 Pharmaceuticals 0000 0000000 00
Callidus Biopharma 21-Nov-2013 Merger/Acquisition 0000 Drug Delivery 0000 0000000 00
To view this company’s complete investment and acquisition history, request access »

Amicus Therapeutics Executive Team (12)

Name Title Board
Seat
Contact
Info
John Crowley JD Chief Executive Officer & Chairman
Bradley Campbell Chief Operating Officer & Board Member
Ellen Rosenberg JD Secretary & Chief Legal Officer
Hung Do Chief Scientific Officer
Jay Barth MD Chief Medical Officer

7 Former Executives

You’re viewing 5 of 12 executives. Get the full list »

Amicus Therapeutics Board Members (16)

Name Representing Role Since Contact
Info
0000000 00000000 Amicus Therapeutics Chief Operating Officer & Board Member 000 0000
00000 0000000 Self Board Member 000 0000
00000 0000000000 Self Board Member 000 0000
0000 0000000 00 Amicus Therapeutics Chief Executive Officer & Chairman 000 0000
00000000 0000000 Self Board Member 000 0000

8 Former Board Members

You’re viewing 5 of 16 board members. Get the full list »